Terms: = Lymphoma AND SET, I2PP2A, 6418, ENSG00000119335, TAF-IBETA, PHAPII, IGAAD, 2PP2A AND Treatment
893 results:
1. SOX11/PRDX2 axis modulates redox homeostasis and chemoresistance in aggressive mantle cell lymphoma.
De Bolòs A; Sureda-Gómez M; Carreras-Caballé M; Rodríguez ML; Clot G; Beà S; Giné E; Campo E; Balsas P; Amador V
Sci Rep; 2024 Apr; 14(1):7863. PubMed ID: 38570586
[TBL] [Abstract] [Full Text] [Related]
2. Lysine demethylase LSD1 is associated with stemness in EBV-positive B cell lymphoma.
Kim JH; Park C; Kim WS
Sci Rep; 2024 Mar; 14(1):6764. PubMed ID: 38514636
[TBL] [Abstract] [Full Text] [Related]
3. Interesting case of regional left ventricular hypertrophy.
Elsaid A; Egdell R; Singh V; Russell S
BMJ Case Rep; 2024 Mar; 17(3):. PubMed ID: 38490700
[TBL] [Abstract] [Full Text] [Related]
4. An ensemble-acute lymphoblastic leukemia model for acute lymphoblastic leukemia image classification.
Huang ML; Huang ZB
Math Biosci Eng; 2024 Jan; 21(2):1959-1978. PubMed ID: 38454670
[TBL] [Abstract] [Full Text] [Related]
5. Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial.
Liu Y; Ping L; Song Y; Tang Y; Zheng W; Liu W; Ying Z; Zhang C; Wu M; Feng F; Lin N; Tu M; Zhu J; Xie Y
BMC Med; 2024 Mar; 22(1):107. PubMed ID: 38454451
[TBL] [Abstract] [Full Text] [Related]
6. Post Renal Transplant Malignancies; A Basic Concept.
Nabi Z; Zahid T; Nabi R
J Ayub Med Coll Abbottabad; 2023; 35(4):664-668. PubMed ID: 38406957
[TBL] [Abstract] [Full Text] [Related]
7. Socioeconomic status and adiposity in childhood cancer survivors: A cross-sectional retrospective study.
Štrublová L; Kepák T; Kuruczová D; Zlámal F; Holíková M; Kepáková K; Štěrba J; Bienertová-Vašků J
PLoS One; 2024; 19(2):e0298068. PubMed ID: 38363727
[TBL] [Abstract] [Full Text] [Related]
8. Establishment of Twinning Partnership to Improve Pediatric Radiotherapy Outcomes Globally.
Ali N; Amare E; Fekadu A; Awol M; Kayode O; Gebresenbet M; Nasir K; Dresser SA; Schriebmann E; Seife E; Esiashvili N
JCO Glob Oncol; 2024 Feb; 10():e2300345. PubMed ID: 38359372
[TBL] [Abstract] [Full Text] [Related]
9. Utility of contrast-enhanced MRI radiomics features combined with clinical indicators for predicting induction chemotherapy response in primary central nervous system lymphoma.
Wang X; Zhao L; Wang S; Zhao X; Chen L; Sun X; Liu Y; Liu J; Sun S
J Neurooncol; 2024 Feb; 166(3):451-460. PubMed ID: 38308802
[TBL] [Abstract] [Full Text] [Related]
10. High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial.
Schorb E; Isbell LK; Kerkhoff A; Mathas S; Braulke F; Egerer G; Röth A; Schliffke S; Borchmann P; Brunnberg U; Kroschinsky F; Möhle R; Rank A; Wellnitz D; Kasenda B; Pospiech L; Wendler J; Scherer F; Deckert M; Henkes E; von Gottberg P; Gmehlin D; Backenstraß M; Jensch A; Burger-Martin E; Grishina O; Fricker H; Malenica N; Orbán A; Duyster J; Ihorst G; Finke J; Illerhaus G
Lancet Haematol; 2024 Mar; 11(3):e196-e205. PubMed ID: 38301670
[TBL] [Abstract] [Full Text] [Related]
11. Communication About Chimeric Antigen Receptor T-Cell (CAR-T) Therapy.
Dhawale T; Johnson PC; Boateng K; Barata A; Traeger L; Nelson AM; Lavoie MW; Holmbeck K; Choe J; Nabily A; Tripathi A; Amonoo HL; Frigault M; El-Jawahri A
Transplant Cell Ther; 2024 Apr; 30(4):402.e1-402.e12. PubMed ID: 38262530
[TBL] [Abstract] [Full Text] [Related]
12. A comprehensive study for selecting optimal treatment modalities for blood cancer in a Fermatean fuzzy dynamic environment.
Alghazzawi D; Noor A; Alolaiyan H; El-Wahed Khalifa HA; Alburaikan A; Dai S; Razaq A
Sci Rep; 2024 Jan; 14(1):1896. PubMed ID: 38253693
[TBL] [Abstract] [Full Text] [Related]
13. Real-world effectiveness and safety of ibrutinib in relapsed/refractory mantle cell lymphoma in Japan: post-marketing surveillance.
Maruyama D; Omi A; Nomura F; Touma T; Noguchi Y; Takebe K; Izutsu K
Int J Hematol; 2024 Feb; 119(2):146-155. PubMed ID: 38195971
[TBL] [Abstract] [Full Text] [Related]
14. The gene expression profile and cell of origin of canine peripheral T-cell lymphoma.
Owens E; Harris L; Harris A; Yoshimoto J; Burnett R; Avery A
BMC Cancer; 2024 Jan; 24(1):18. PubMed ID: 38166662
[TBL] [Abstract] [Full Text] [Related]
15. Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma.
Goto H; Ito S; Kizaki M; Yamaguchi M; Fukuhara N; Kato K; Saito T; Terui Y; Okubo S; Soshin T; Zeng J; Honda H; Badawi M; Ross JA; Izutsu K
Int J Clin Oncol; 2024 Feb; 29(2):232-240. PubMed ID: 38157190
[TBL] [Abstract] [Full Text] [Related]
16. Targeting of the CD161 inhibitory receptor enhances T-cell-mediated immunity against hematological malignancies.
Alvarez Calderon F; Kang BH; Kyrysyuk O; Zheng S; Wang H; Mathewson ND; Luoma AM; Ning X; Pyrdol J; Cao X; Suvà ML; Yuan GC; Wittrup KD; Wucherpfennig KW
Blood; 2024 Mar; 143(12):1124-1138. PubMed ID: 38153903
[TBL] [Abstract] [Full Text] [Related]
17.
Choi YJ; Min YK; Lee ST; Choi JR; Shin S
Ann Lab Med; 2024 Jul; 44(4):335-342. PubMed ID: 38145892
[TBL] [Abstract] [Full Text] [Related]
18. Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy.
Voltin CA; Paccagnella A; Winkelmann M; Heger JM; Casadei B; Beckmann L; Herrmann K; Dekorsy FJ; Kutsch N; Borchmann P; Fanti S; Kunz WG; Subklewe M; Kobe C; Zinzani PL; Stelljes M; Roth KS; Drzezga A; Noppeney R; Rahbar K; Reinhardt HC; von Tresckow B; Seifert R; Albring JC; Blumenberg V; Farolfi A; Flossdorf S; Gödel P; Hanoun C
Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1361-1370. PubMed ID: 38114616
[TBL] [Abstract] [Full Text] [Related]
19. Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell lymphoma Consortium.
Vose JM; Fu K; Wang L; Mansoor A; Stewart D; Cheng H; Smith L; Yuan J; Qureishi HN; Link BK; Cessna MH; Barr PM; Kahl BS; Mckinney MS; Khan N; Advani RH; Martin P; Goy AH; Phillips TJ; Mehta A; Kamdar M; Crump M; Pro B; Flowers CR; Jacobson CA; Smith SM; Stephens DM; Bachanova V; Jin Z; Wu S; Hernandez-Ilizaliturri F; Torka P; Anampa-Guzmán A; Kashef F; Li X; Sharma S; Greiner TC; Armitage JO; Lunning M; Weisenburger DD; Bociek RG; Iqbal J; Yu G; Bi C;
J Hematol Oncol; 2023 Dec; 16(1):122. PubMed ID: 38104096
[TBL] [Abstract] [Full Text] [Related]
20. Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study.
Song Y; Malpica L; Cai Q; Zhao W; Zhou K; Wu J; Zhang H; Mehta-Shah N; Ding K; Liu Y; Li Z; Zhang L; Zheng M; Jin J; Yang H; Shuang Y; Yoon DH; Gao S; Li W; Zhai Z; Zou L; Xi Y; Koh Y; Li F; Prince M; Zhou H; Lin L; Liu H; Allen P; Roncolato F; Yang Z; Kim WS; Zhu J
Lancet Oncol; 2024 Jan; 25(1):117-125. PubMed ID: 38092009
[TBL] [Abstract] [Full Text] [Related]
[Next]
